Human ES and iPS cells as cell sources for the treatment of Parkinson's disease

Current state and problems

Dong Youn Hwang, Dae-Sung Kim, Dong Wook Kim

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamine (mDA) neuron-like cells, which would be directly translated into high effectiveness of the therapy with minimum risk of undesirable side effects. Due to fruitful efforts from many laboratories, a variety of strategies for improving efficiency of dopaminergic differentiation from hESCs have been developed, mostly by optimizing culture conditions, genetic modification, and modulating intracellular signaling pathways. The rapid advances in the fields of dopaminergic differentiation of hESCs, prevention of tumor formation, and establishment of safe human induced pluripotent stem cells (hiPSCs) would open the door to highly effective, tumor-free, and immune rejection-free cell therapy for PD in the near future.

Original languageEnglish
Pages (from-to)292-301
Number of pages10
JournalJournal of cellular biochemistry
Volume109
Issue number2
DOIs
Publication statusPublished - 2010 Feb 1
Externally publishedYes

Fingerprint

Stem cells
Parkinson Disease
Cell- and Tissue-Based Therapy
Tumors
Therapeutics
Induced Pluripotent Stem Cells
Neurodegenerative diseases
Dopaminergic Neurons
Mesencephalon
Neurodegenerative Diseases
Neoplasms
Cell culture
Neurons
Human Embryonic Stem Cells
Dopamine

Keywords

  • Dopamine neuron differentiation
  • Human ES/IPS cells
  • Pakinson's disease

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Human ES and iPS cells as cell sources for the treatment of Parkinson's disease : Current state and problems. / Hwang, Dong Youn; Kim, Dae-Sung; Kim, Dong Wook.

In: Journal of cellular biochemistry, Vol. 109, No. 2, 01.02.2010, p. 292-301.

Research output: Contribution to journalReview article

@article{e61ddb74b423435987f8dccd20f3a555,
title = "Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: Current state and problems",
abstract = "Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamine (mDA) neuron-like cells, which would be directly translated into high effectiveness of the therapy with minimum risk of undesirable side effects. Due to fruitful efforts from many laboratories, a variety of strategies for improving efficiency of dopaminergic differentiation from hESCs have been developed, mostly by optimizing culture conditions, genetic modification, and modulating intracellular signaling pathways. The rapid advances in the fields of dopaminergic differentiation of hESCs, prevention of tumor formation, and establishment of safe human induced pluripotent stem cells (hiPSCs) would open the door to highly effective, tumor-free, and immune rejection-free cell therapy for PD in the near future.",
keywords = "Dopamine neuron differentiation, Human ES/IPS cells, Pakinson's disease",
author = "Hwang, {Dong Youn} and Dae-Sung Kim and Kim, {Dong Wook}",
year = "2010",
month = "2",
day = "1",
doi = "10.1002/jcb.22411",
language = "English",
volume = "109",
pages = "292--301",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Human ES and iPS cells as cell sources for the treatment of Parkinson's disease

T2 - Current state and problems

AU - Hwang, Dong Youn

AU - Kim, Dae-Sung

AU - Kim, Dong Wook

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamine (mDA) neuron-like cells, which would be directly translated into high effectiveness of the therapy with minimum risk of undesirable side effects. Due to fruitful efforts from many laboratories, a variety of strategies for improving efficiency of dopaminergic differentiation from hESCs have been developed, mostly by optimizing culture conditions, genetic modification, and modulating intracellular signaling pathways. The rapid advances in the fields of dopaminergic differentiation of hESCs, prevention of tumor formation, and establishment of safe human induced pluripotent stem cells (hiPSCs) would open the door to highly effective, tumor-free, and immune rejection-free cell therapy for PD in the near future.

AB - Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamine (mDA) neuron-like cells, which would be directly translated into high effectiveness of the therapy with minimum risk of undesirable side effects. Due to fruitful efforts from many laboratories, a variety of strategies for improving efficiency of dopaminergic differentiation from hESCs have been developed, mostly by optimizing culture conditions, genetic modification, and modulating intracellular signaling pathways. The rapid advances in the fields of dopaminergic differentiation of hESCs, prevention of tumor formation, and establishment of safe human induced pluripotent stem cells (hiPSCs) would open the door to highly effective, tumor-free, and immune rejection-free cell therapy for PD in the near future.

KW - Dopamine neuron differentiation

KW - Human ES/IPS cells

KW - Pakinson's disease

UR - http://www.scopus.com/inward/record.url?scp=74949118218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949118218&partnerID=8YFLogxK

U2 - 10.1002/jcb.22411

DO - 10.1002/jcb.22411

M3 - Review article

VL - 109

SP - 292

EP - 301

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 2

ER -